Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Kalbitor is a prescription plasma kallikrein inhibitor containing ecallantide. It is indicated for treatment of acute hereditary angioedema attacks in adults and adolescents age 12 and older. Each single-dose vial contains 10 mg of ecallantide in 1 mL.
read more about kalbitor ...Ecallantide selectively and reversibly inhibits plasma kallikrein. This reduces conversion of high-molecular-weight kininogen to bradykinin, a mediator involved in swelling during hereditary angioedema attacks.
Kalbitor is used for acute hereditary angioedema attacks in patients age 12 and older. Safety and efficacy are not established below age 12. A healthcare professional administers treatment in a setting prepared to manage both hereditary angioedema and anaphylaxis.
The recommended dose is 30 mg subcutaneously as three separate 10 mg injections. If the attack persists, one additional 30 mg dose can be administered within 24 hours. Injection sites include the abdomen, thigh, or upper arm.
Kalbitor carries a boxed warning for anaphylaxis. Anaphylaxis occurred in 4 percent of treated patients in the clinical program, and its symptoms can resemble an acute hereditary angioedema attack. Patients are monitored closely after administration, and known clinical hypersensitivity to Kalbitor is a contraindication.
Kalbitor treats acute hereditary angioedema attacks in patients age 12 and older.
One dose is 30 mg given as three separate 10 mg subcutaneous injections.
Yes. One additional 30 mg dose can be administered within 24 hours.
Yes. The boxed warning concerns anaphylaxis.
Ecallantide for the Treatment of Acute Attacks in Hereditary Angioedema. https://pubmed.ncbi.nlm.nih.gov/20818887/. Date Accessed October 7, 2026.
EDEMA4: A Phase 3, Double-Blind Study of Subcutaneous Ecallantide Treatment for Acute Attacks of Hereditary Angioedema. https://pubmed.ncbi.nlm.nih.gov/20568386/. Date Accessed October 7, 2026.
KALBITOR (Ecallantide) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f56aec67-c662-477c-b866-bfc23e8809cf. Date Accessed October 7, 2026.
Prospective, Double-Blind, Placebo-Controlled Trials of Ecallantide for Acute Attacks of Hereditary Angioedema. https://pubmed.ncbi.nlm.nih.gov/22149337/. Date Accessed October 7, 2026.
Search Orphan Drug Designations and Approvals: Ecallantide. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=160802. Date Accessed October 7, 2026.